Beijing, October 20, 2023 – RDPAC officially announces the new Chair and Vice-Chairs of the Executive Committee for the 2024-2025 term. Based on the results of the nomination and election process, Jean-Christophe Pointeau, Pfizer China President, will serve another term as the Chair of the RDPAC Executive Committee for 2024-2025. Ingrid Zhang, President of Novartis China, and Christine Zhou, SVP & President of Region China at Novo Nordisk, will continue their roles as Vice-Chairs of the Executive Committee.
The Chair and Vice-Chairs of the RDPAC 2024-2025 Executive Committee were elected through a nomination process involving 13 members of the RDPAC Executive Committee for the term 2024-2025. With this announcement, the transition of the RDPAC Executive Committee for the 2024-2025 term has been successfully completed.
Jean-Christophe Pointeau
Chair of the RDPAC 2024-2025 Executive Committee, Pfizer China President
"I am very honored to have been re-elected as the Chairman of RDPAC," said Jean-Christophe Pointeau, Chair of the RDPAC 2024-2025 Executive Committee. "As an industry organization, RDPAC will be continuously committed to supporting the establishment of a scientific and efficient drug regulatory system aligned with international standards. We will continue to promote the development of innovative healthcare support systems, strengthen legal frameworks for pharmaceutical innovation protection, enhance industry compliance, foster a vibrant pharmaceutical innovation ecosystem, and promote the high-quality development of China's pharmaceutical industry. These efforts are geared towards making substantial contributions to the 'Healthy China 2030' initiative.”. With nearly 30 years of international experience in the pharmaceutical industry and extensive leadership roles in multinational pharmaceutical companies in China, Jean-Christophe Pointeau brings invaluable expertise. He has previously served as the President of BMS China and the President of Sanofi China. Having chaired the RDPAC Executive Committee in the 2018-2019 and 2022-2023 terms, he has played a significant role in advancing policy and environmental reforms within the pharmaceutical industry.
Ingrid Zhang
Vice-Chair of the 2024-2025 RDPAC Executive Committee, President of Novartis China
Ingrid Zhang, the Vice-Chair of the 2024-2025 RDPAC Executive Committee, stated, “I am deeply honored to have been re-elected as the Vice Chair of the RDPAC Executive Committee. The pharmaceutical industry in China has undergone remarkable and rapid growth in recent years, propelled by innovation as the guiding force. RDPAC, serving as a pivotal industry organization uniting numerous innovative pharmaceutical companies, holds a vital position in shaping our trajectory. We are steadfast in our commitment to fostering close collaboration with diverse stakeholders within the healthcare ecosystem, further cultivating an environment that nurtures innovation. Our collective goal is to expedite the introduction and accessibility of innovative medicines, thereby bolstering public health and contributing significant value to social development."
Christine Zhou
Vice-Chair of the RDPAC 2024-2025 Executive Committee, SVP & President of Region China at Novo Nordisk
“As partners of ‘Healthy China’, RDPAC members have joined hands and will continue to foster innovation and promote the high-quality development of the pharmaceutical industry, enabling Chinese patients with unmet medical needs to have earlier access to global innovative medicines and contributing to China's pharmaceutical innovation ecosystem. In addition, member companies have worked closely with partners to build an efficient and high-quality healthcare system. From being a clinical physician to a nearly 30-year career in the pharmaceutical industry, my intention to help patients has never changed. As Vice-Chairperson, I will continue to work collaboratively with the Chairman, Vice-Chairperson, Executive Committee members, all China country heads, and other healthcare stakeholders, to drive the sustainable development of our industry and benefit more Chinese patients.” said Christine Zhou, Vice-Chair of the RDPAC 2024-2025 Executive Committee.
--------------------------------------------------------------------------------
Over the next two years, under the guidance of the new Executive Committee leadership, RDPAC will continue to collaborate with key stakeholders, foster international cooperation, bridge communication between the government and the industry, advocate for sustainable policies that incentivize pharmaceutical innovation to ensure novel medicines benefit Chinese patients as early and as extensively as possible. Simultaneously, RDPAC will be continuously dedicated to elevating China's pharmaceutical innovation ecosystem to foster higher-quality industry development, and to contributing to ‘Healthy China’ to improve the health and well-being of people in China.
